Skip to main content
Displaying 1 - 12 of 16
Display:
12
24
48
Liver Tumours
5
Bayer: Addressing a Changing Treatment Dynamic in HCC: Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Bayer: Addressing a Changing Treatment Dynamic in HCC: Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Bayer: Addressing a Changing Treatment Dynamic in HCC: Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Bayer: Addressing a Changing Treatment Dynamic in HCC: Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Bayer: Addressing a Changing Treatment Dynamic in HCC: Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
6
Boston Scientific: SIRT: The versatility of current HCC treatment & the opportunities for the future - Digital Liver Cancer Summit 2021
View
Liver Tumours
6
Boston Scientific: SIRT: The versatility of current HCC treatment & the opportunities for the future - Digital Liver Cancer Summit 2021
View
Pagination
Current page
1
Page
2
Next page
next ›
Last page
Last »
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Content Access policy
Privacy Policy
Cookie Policy